• Top page
  • Timetable
  • Per session
  • Per presentation
  • How to
  • Meeting Planner



Neuroprotection, Neurotoxicity and Neuroinflammation

開催日 2014/9/11
時間 11:00 - 12:00
会場 Poster / Exhibition(Event Hall B)

Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by regulating the neuroprotective inflammatory response of microglia and T cells

  • P1-331
  • 遠藤 史人 / Fumito Endo:1 小峯 起 / Okiru Komine:1 山中 宏二 / Koji Yamanaka:1 
  • 1:名古屋大学 / Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University 

Neuroinflammation, characterized by production of proinflammatory cytokines and other toxic / protective molecules followed by the activation of glial cells and the infiltration of immune cells, is involved in the pathomechanism of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Elevated level of transforming growth factor-β1 (TGF-β1), an anti-inflammatory cytokine, has been observed in the peripheral blood and the cerebrospinal fluid of ALS patients. However, the exact role of TGF-β1 in ALS has not been elucidated. We show that TGF-β1 level is elevated in activated astrocytes of the lumbar spinal cord of of mutant superoxide dismutase 1 (SOD1G93A) mice and that astrocyte-specific overproduction of TGF-β1 in SOD1G93A mice accelerates later disease progression in a non-cell autonomous manner with deactivated microglia, and fewer infiltrated T cells, leading to reduced IGF-I and CD11c expressions of microglia. On the other hand, we also show that astrocyte-specific downregulation of mutant SOD1 in SOD1G37R mice slows later disease progression with lower levels of TGF-β1. Moreover, endogenous TGF-β1 levels in SOD1G93A mice negatively correlate with survival time. These findings indicate that astrocyte-derived TGF-β1 is a determinant of the disease progression of ALS mice by regulating the neuroprotective inflammatory response by microglia and T cells. Furthermore, targeting TGF-β1 in the cell-type specific manner can be a viable therapeutic candidate in ALS.

Copyright © Neuroscience2014. All Right Reserved.